Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines

Hematological Oncology

Volumn 25, Issue 4, 2007, Pages 198-203

  Rigacci, Luigi ^a   Mappa, Silvia ^a   Nassi, Luca ^a   Alterini, Renato ^a   Carrai, Valentina ^a   Bernardi, Franco ^a   Bosi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Doxorubicin; Liposomal doxorubicin; Non Hodgkin's lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PREDNISONE; PREMEDICATION; STROKE VOLUME; TREATMENT OUTCOME; VINCRISTINE;

EID: 37649022460     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.827     Document Type: Article

References (29)

1. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
2. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opinion Drug Saf 2006; 5: 791-809.
3. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002; 346: 235-242.
4. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561-578.
5. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004; 22: 1864-1871.
6. Kanter PM, Bullard GA, Pilkiewicz FG, et al. Preclinical toxicology study of liposome-encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 1993; 7: 85-95.
7. Kanter PM, Bullard GA, Ginsberg RA, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 1993; 7: 17-26.
8. Nayar R, Mayer LD, Masin D, et al. Antitumor activity of liposomal encapsulated doxorubicin in different murine tumor models: implications for mechanisms of action. Proc Am Assoc Cancer Res 1990; 31: 429; (abstr 2549).
9. Ostro MJ. Liposomes: from the bench to the marketplace - Doxorubicin as an example. In Liposomes in the Therapy of Infectious Diseases and Cancer, Fidler IJ, Lopez-Berestein G (eds). Alan Liss, Inc.: New York, USA, 1989; 155-163.
10. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990; 53: 183-190.
11. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
12. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and genetics of tumors of haematopoietic and lymphoid tissues, IARC Press: Lyon, France, JARC Press, 2001.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
14. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
16. National Cancer Institute: Common Toxicity Criteria. National Institutes of Health: Bethesda, MD.
17. SPSS for Windows, Version 8.0, SPSS Inc., U.S.A. 1998.
18. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-1332.
19. Swain SM, Whaley FS, Gerber MC, Ewers MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15: 1333-1340.
20. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 19: 133-139.
21. Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target 1996; 4: 129-140.
22. Stewart S, Harrington KJ. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 1997; 11: S33-37.
23. Bland M. An Introduction to Medical Statistics (2nd edn). Oxford University Press: Oxford, UK, 1995; 119-126.
24. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2 2002; 94: 25-36.
25. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22: 2662-2670.
26. Federico M, Caballero MD, Thiel E, Bologna S, Dyer MJS, Luminari S. A phase II study of cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin (Myocet), and prednisone plus rituximab (R-COMP) in elderly patients with diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2006; 24(18S):17506.
27. Garcia Arroyo FR, Herrero J, Provencio M, Gòmez-Codina J, Rueda A, Llanos Gotel M. Safety analysis of a phase II study of cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin (Myocet),and prednisone plus rituximab in biweekly regimen (R-COMP-14) as primary treatment of non-Hodgkin lymphoma. J Clin Oncol 2006; 24(18S): 17532.
28. Tulpule A, Espina BM, Berman N, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006; 7: 59-64.
29. Mrozek E, Rhoades CA, Allen J, Hade EM, Shapiro CL. Phase I trial of liposomal encapsulated doxorubicin (Myocet; DC-99) and weekly docetaxel in advanced breast cancer patients. Ann Oncol 2005; 16: 1087-1093.